Johnson & Johnson Shares Close in on 52-Week Low - Market Mover
The shares closed 0.3% above its 52-week low of $150.71, with trading volume higher than its 30 day average
Mar 23, 2023 by Kwhen Finance Editors
Johnson & Johnson (JNJ) shares closed today at 0.3% above its 52 week low of $150.71, giving the company a market cap of $471B. The stock is currently down 13.9% year-to-date, down 11.3% over the past 12 months, and up 35.4% over the past five years. This week, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 1.1%.
Trading Activity
- Trading volume this week was 7.7% lower than the 20-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.3.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
- MACD, a trend-following momentum indicator, indicates an upward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
Fundamentals & Catalysts
- Over the past 12 months the company generated $28 billion in earnings before interest and taxes from $84 billion in revenue. It currently holds $24 billion in cash and $40 billion in debt.
- Its forward price-to-earnings (P/E) ratio of 0 is lower than its current P/E ratio of 26.27, implying that analysts are expecting an increase in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at -2.51. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 2.62 which means it currently has $2.62 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 6.77. This means that the stock is trading at a premium of 7 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 5.29.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 5.40.
P/E
26.27
EBITDA
$28B
P/Book
6.77
Mkt Cap
$471B
P/Sales
5.29
Revenue
$84B
EPS (TTM)
6.73
PEG Ratio
-2.51
EV/Revenue
5.40
Total Cash
$24B
Debt/Equity
2.62
Forward P/E
0.00
Current Debt
$40B
Gross Profit
$55B
Dividend Date
-
Earnings Date
2023-04-18
Profit Margin
0.18
Revenue/Share
31.98
Total Revenue
$84B
Enterprise Val
$454B
Put/Call Ratio
0.79
Revenue/Employee
0.00
Market Comparative Performance
- The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Johnson & Johnson | 0.1 | -13.9 | -11.3 | -16.9 | 0.2 |
| Dow Jones Industrial Average | 0.2 | -2.9 | -6.2 | -7.7 | 13.2 |
| S&P 500 Index | 0.3 | 2.9 | -11.3 | -13.1 | 14.4 |
| Health Care | -0.4 | -6.3 | -6.6 | -10.9 | 8.5 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by 201.4%
- The company's stock price performance over the past 12 months lags the peer average by 1143.1%
- The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 10.9% higher than the average peer.
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Johnson & Johnson | JNJ | 26.3 | -13.9 | -11.3 | -16.9 | 0.2 |
| Peer Avg | N/A | 23.7 | -4.6 | -0.9 | -14.8 | 15.8 |
| Lilly(Eli) & Co | LLY | 50.4 | -9.2 | 17.6 | -13.7 | 21.0 |
| Merck & Co Inc | MRK | 18.3 | -5.2 | 35.6 | -9.2 | 34.5 |
| Pfizer Inc. | PFE | 7.2 | -21.2 | -22.0 | -26.2 | 2.4 |
| Novartis AG - ADR | NVS | 28.3 | -5.7 | -0.5 | -8.5 | 16.4 |
| Abbott Laboratories | ABT | 24.3 | -11.4 | -19.1 | -21.0 | 4.4 |
| Sanofi - ADR | SNY | 13.7 | 0.7 | -2.1 | ||
| Medtronic Plc | MDT | 25.9 | 2.9 | -24.4 | -28.3 | 6.5 |
| Stryker Corp. | SYK | 43.8 | 11.4 | 3.3 | -3.8 | 45.6 |
| Gilead Sciences, Inc. | GILD | 21.1 | -8.5 | 35.2 | ||
| Glaxosmithkline plc - ADR | GSK | 3.9 | 0.3 | -32.9 | -37.2 | 27.1 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: